(CYTK) Cytokinetics - Ratings and Ratios
Cardiac Activator, Skeletal Activator, Cardiac Inhibitor
Dividends
Currently no dividends paid| Risk via 10d forecast | |
|---|---|
| Volatility | 54.5% |
| Value at Risk 5%th | 77.5% |
| Relative Tail Risk | -13.52% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.58 |
| Alpha | 14.85 |
| CAGR/Max DD | 0.18 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.544 |
| Beta | 0.610 |
| Beta Downside | 0.578 |
| Drawdowns 3y | |
|---|---|
| Max DD | 72.39% |
| Mean DD | 40.70% |
| Median DD | 42.97% |
Description: CYTK Cytokinetics November 05, 2025
Cytokinetics Inc. (NASDAQ:CYTK) is a late-stage biotech that designs small-molecule muscle activators and inhibitors to treat serious U.S. diseases. Its lead programs are omecamtiv mecarbil (a cardiac myosin activator in Phase III for heart failure), CK-089 (a fast skeletal muscle troponin activator in Phase I), CK-586 (a cardiac myosin inhibitor in Phase II), and aficamten (an oral cardiac myosin inhibitor in Phase III for hypertrophic cardiomyopathy). The company also holds a strategic alliance with Ji Xing Pharmaceuticals for aficamten’s development and commercialization in Japan.
As of the latest quarterly filing, Cytokinetics reported a cash runway of roughly $250 million, supporting its R&D spend of about $120 million year-to-date. The Phase III GALACTIC-HF trial for omecamtiv mecarbil is slated for data readout in Q2 2026, while aficamten’s Phase III trial (EXPLORER-HCM) expects results by early 2025. The firm’s market capitalization hovers near $1.3 billion, reflecting investor weighting of these late-stage assets.
The cardiovascular biotech sector is being driven by an aging U.S. population and the expanding prevalence of heart failure, projected to affect over 6 million Americans by 2030. Concurrently, the biotech funding environment remains favorable, with venture capital allocating roughly $30 billion annually to early-stage therapeutics, but late-stage companies like CYTK must demonstrate clear regulatory milestones to sustain valuation.
For a deeper, data-rich perspective on CYTK’s risk-adjusted upside, you may find it worthwhile to explore the analyst tools on ValueRay.
Piotroski VR‑10 (Strict, 0-10) 0.0
| Net Income (-751.9m TTM) > 0 and > 6% of Revenue (6% = 5.23m TTM) |
| FCFTA -0.32 (>2.0%) and ΔFCFTA -3.22pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 957.7% (prev 28.2k%; Δ -27.3kpp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.30 (>3.0%) and CFO -432.9m > Net Income -751.9m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 6.88 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (120.0m) change vs 12m ago 1.95% (target <= -2.0% for YES) |
| Gross Margin -127.5% (prev -10.2k%; Δ 10.0kpp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 6.07% (prev 0.22%; Δ 5.85pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -6.82 (EBITDA TTM -646.2m / Interest Expense TTM 96.1m) >= 6 (WARN >= 3) |
Altman Z'' -8.52
| (A) 0.58 = (Total Current Assets 977.3m - Total Current Liabilities 142.1m) / Total Assets 1.44b |
| (B) -2.30 = Retained Earnings (Balance) -3.30b / Total Assets 1.44b |
| warn (B) unusual magnitude: -2.30 — check mapping/units |
| (C) -0.46 = EBIT TTM -655.8m / Avg Total Assets 1.44b |
| (D) -1.69 = Book Value of Equity -3.30b / Total Liabilities 1.96b |
| Total Rating: -8.52 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 35.42
| 1. Piotroski 0.0pt |
| 2. FCF Yield -5.42% |
| 3. FCF Margin data missing |
| 4. Debt/Equity -2.30 |
| 5. Debt/Ebitda -1.50 |
| 7. RoE 232.9% |
| 8. Rev. Trend -18.06% |
| 9. EPS Trend -60.30% |
What is the price of CYTK shares?
Over the past week, the price has changed by -3.53%, over one month by -3.93%, over three months by +23.90% and over the past year by +26.11%.
Is CYTK a buy, sell or hold?
- Strong Buy: 9
- Buy: 9
- Hold: 3
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the CYTK price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 79.6 | 25.6% |
| Analysts Target Price | 79.6 | 25.6% |
| ValueRay Target Price | 68.4 | 8% |
CYTK Fundamental Data Overview December 06, 2025
P/S = 93.2854
P/B = 60.3093
P/EG = -0.42
Beta = 0.592
Revenue TTM = 87.2m USD
EBIT TTM = -655.8m USD
EBITDA TTM = -646.2m USD
Long Term Debt = 1.05b USD (from longTermDebt, last quarter)
Short Term Debt = 37.9m USD (from shortTermDebt, last quarter)
Debt = 1.20b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 968.3m USD (from netDebt column, last quarter)
Enterprise Value = 8.37b USD (8.14b + Debt 1.20b - CCE 962.5m)
Interest Coverage Ratio = -6.82 (Ebit TTM -655.8m / Interest Expense TTM 96.1m)
FCF Yield = -5.42% (FCF TTM -453.4m / Enterprise Value 8.37b)
FCF Margin = -519.9% (FCF TTM -453.4m / Revenue TTM 87.2m)
Net Margin = -862.2% (Net Income TTM -751.9m / Revenue TTM 87.2m)
Gross Margin = -127.5% ((Revenue TTM 87.2m - Cost of Revenue TTM 198.4m) / Revenue TTM)
Gross Margin QoQ = -38.38% (prev 96.58%)
Tobins Q-Ratio = 5.83 (Enterprise Value 8.37b / Total Assets 1.44b)
Interest Expense / Debt = 2.20% (Interest Expense 26.3m / Debt 1.20b)
Taxrate = 21.0% (US default 21%)
NOPAT = -518.1m (EBIT -655.8m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 6.88 (Total Current Assets 977.3m / Total Current Liabilities 142.1m)
Debt / Equity = -2.30 (negative equity) (Debt 1.20b / totalStockholderEquity, last quarter -521.1m)
Debt / EBITDA = -1.50 (negative EBITDA) (Net Debt 968.3m / EBITDA -646.2m)
Debt / FCF = -2.14 (negative FCF - burning cash) (Net Debt 968.3m / FCF TTM -453.4m)
Total Stockholder Equity = -322.9m (last 4 quarters mean from totalStockholderEquity)
RoA = -52.34% (Net Income -751.9m / Total Assets 1.44b)
RoE = 232.9% (negative equity) (Net Income TTM -751.9m / Total Stockholder Equity -322.9m)
RoCE = -90.41% (EBIT -655.8m / Capital Employed (Equity -322.9m + L.T.Debt 1.05b))
RoIC = -114.1% (out of range, set to none) (NOPAT -518.1m / Invested Capital 454.2m)
WACC = 7.42% (E(8.14b)/V(9.33b) * Re(8.26%) + D(1.20b)/V(9.33b) * Rd(2.20%) * (1-Tc(0.21)))
Discount Rate = 8.26% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 10.05%
Fair Price DCF = unknown (Cash Flow -453.4m)
EPS Correlation: -60.30 | EPS CAGR: -53.23% | SUE: -3.60 | # QB: 0
Revenue Correlation: -18.06 | Revenue CAGR: -59.15% | SUE: -0.18 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-1.59 | Chg30d=+0.003 | Revisions Net=+1 | Analysts=3
EPS next Year (2026-12-31): EPS=-5.98 | Chg30d=-0.254 | Revisions Net=+2 | Growth EPS=-0.1% | Growth Revenue=+66.9%
Additional Sources for CYTK Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle